Engrail Therapeutics, a San Diego, CA-based neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies, raised a $32m extension of Series A financing, which brings the total round to $64m.
Nan Fung Life Sciences (NFLS), the global investment platform of the Nan Fung Group, led this round following their leadership of the original Series A raise.
The company will use the proceeds to finance the advancement of their diverse pipeline, including its lead assets, ENX-101, ENX-102 and internal preclinical programs.
Led by Vikram Sudarsan, Ph.D., CEO and president, Engrail Therapeutics has assembled a diverse portfolio of assets with validated mechanisms through its dynamic model for advancing drugs aimed at treating life-limiting diseases of the nervous system. By adopting a ‘science-first’ approach, combined with a comprehensive view of clinical development strategy, regulatory considerations and intellectual property, the company can find differentiated assets with validated mechanisms of action for diseases where significant patient need still exists.